

October 8, 2015



OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) today announced that the company will host a symposium at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology and will present the complete 12-month pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO's weekly long-acting growth hormone (hGH-CTP) in naïve growth hormone deficient children. The 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology is taking place in Tokyo, Japan from October 8-10.

The data to be presented include results for 53 naïve growth hormone deficient children completing twelve months of weekly treatment with hGH-CTP. This phase 2 study was a one year, dose finding study administering hGH-CTP to growth hormone deficient children once a week using Genotropin® as a daily comparator arm. The twelve months data confirm comparable response of hGH-CTP to daily Genotropin® as reflected by the twelve months IGF-1SDS profile, annual HV, HV SDS and safety profile.

OPKO's symposium will be held on Friday, Oct. 10, 2015 at 1.30pm.

ABOUT OPKO HEALTH

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit <http://www.opko.com>.

SAFE HARBOR STATEMENT

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected benefits of hGH-CTP, whether OPKO's clinical trials for adult and pediatric growth hormone deficiency will generate data to support marketing approval, whether hGH-CTP will be successfully developed or commercialized, expectations regarding the product and its market potential, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or

results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151008005110/en/>

OPKO Health, Inc.

Investor Relations, 305-575-4100

or

Media Contacts:

Rooney & Associates

Terry Rooney, 212-223-0689

trooney@rooneyco.com

or

Rooney & Associates

Marion Janic, 212-223-4017

mjanic@rooneyco.com

Source: OPKO Health, Inc.